Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1
This trial is active, not recruiting.
|Sponsor||National Institute on Drug Abuse (NIDA)|
|Start date||September 2001|
|End date||October 2002|
|Trial size||16 participants|
|Trial identifier||NCT00033072, NCT00024882, NIDA-CTO-0004-1|
The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.
safety of selegiline
Male or female participants from 18 years up to 45 years old.
Inclusion Criteria: - Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals - Be able to verbalize understanding of consent form; provide written informed consent Exclusion Criteria: - Please contact site for more information
|Official title||Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline|
|Principal investigator||Thomas Newton, M.D.|
|Description||To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.|
Call for more information